Home » Consulting Services » Business and Data Analysis »

Business and Data Analysis

PHSI uses its vast industry experience along with analysis techniques and financial modeling to solve your toughest business problems. We analyze your situation from different points of view and identify opportunities or potential problems before they occur. Prior to your investment in a new business process or program, let PHSI model and assess its impact on your financial results.

View our case studies related to business and data analysis:

340B Compliance Review

Accounting Firm Required Pharmacy Expertise

Client Selects Copay Reduction Program

Determining Competitive Market Landscape

Drug Resources Made Available via Manufacturer’s Website

Generic Competition Studied to Determine Effects on Brand Drug

Generic Market Forecasting

Industry Monitoring, Research, & Analysis Used as a Vital Decision Resource

Manufacturer Seeks Pre-Launch Rebate Level Forecasting

Medicare PDP Develops Community Pharmacy MTM Program

PBM Contract Variance Analysis

PBM Positions Itself for Increased Rebate Yield

PHSI Helps PBM Develop a Pharmacy Network Contracting Strategy

PHSI Helps Supermarket Chain Move Toward Providing Pharmaceutical Care

Proactive Response to Loss of Brand Patent Protection

Rebate Contracting Consolidation Process Directed by PHSI

Research Updates Brand Designation in Drug Databases

Seasonal-Use Product Reimbursement Trend Analysis

Specialty Drug Reimbursement by Pharmacy Type

U&C Pricing Strategy Critical for Chain Expansion

November 2019 Question of the Month

The new Fair and Accurate Medicaid Pricing Act excludes Authorized Generics (AG) from AMP calculations for brand manufacturers, likely increasing their AMP prices and subsequent rebates. How will this change effect brand manufacturers decision to launch an AG or not?

Brand manufacturer will reconsider when to launch the AG and only launch after an ANDA is approved: 100%

Brand manufacturer will launch the AG before the ANDA is introduced in the market: 0%

The Act will not impact brand manufacturers’ decisions to launch AGs: 0%

Brand manufacturers will not launch AG’s any longer: 0%